UK Pioneers Tailored Biosimilars Pathway With Fresh Guidance
Updated Guidance Setting Out MHRA’s New Licensing Route Welcomed By BBA And IGBA
Executive Summary
Updated guidance on the UK’s new licensing pathway for biosimilars – which will typically not require comparative efficacy data – has been published by the MHRA after a stakeholder consultation, receiving a warm welcome from the off-patent industry both locally and internationally.
You may also be interested in...
Lupin’s Luforbec Launch Leads UK Respiratory Efforts
Following Lupin’s launch of the first UK generic version of Fostair in August, Lupin UK general manager Ben Ellis tells Generics Bulletin how the company is taking full advantage of the opportunity and laying the groundwork for future activities in the respiratory arena.
US FDA Unlikely To Issue Broad Biosimilar Guidance Saying Comparative Clinical Studies Unnecessary
OTBB head Sarah Yim says FDA internal thinking is not aligned on the idea and that a lot of convincing was necessary to drop the clinical study requirement for insulin biosimilars.
US FDA Unlikely To Issue Broad Biosimilar Guidance Saying Comparative Clinical Studies Unnecessary
OTBB head Sarah Yim says FDA internal thinking is not aligned on the idea and that a lot of convincing was necessary to drop the clinical study requirement for insulin biosimilars.